1.Studies on immunomodulatory effects of methanol extracts from Chinese algae
Rongli NIU ; Xiao FAN ; Lijun HAN
Chinese Journal of Immunology 2001;0(10):-
Objective:To study the immunomodulatory effect of extracts from Chinese marine algae, methanol extracts of thirty-nine species were assayed.Methods:The proliferation of T,B lymphocyte and cytotoxic was measured by MTT assay.Results:Among the methanol extracts of algae, 16 showed well concentration-dependent immunomodulatory effects, 6 have exhibited fine dual-immunomodulatory effects at the doses of 1-100 ?g/ml.Conclusion:These results suggest Chinese algae have different immunomodulatory effects and merit further investigation.
2.Practice and experience of diagnostics probation teaching for foreign students
Duo LI ; Rongli WANG ; Xianming FAN ; Xiaoxuan CHENG
Chinese Journal of Medical Education Research 2003;0(02):-
Diagnostics probation teaching has important value in the medical teaching for foreign students. The practice experiences of diagnostics probation teaching for foreign students in the last 3 years are reviewed from the management of teaching,practice of teaching,supervision of teaching and examine of teaching in order to improve the effect of diagnostics probation teaching for foreign students.
3.Determination of Ofloxacin Excretion in Urine by UV - spectrophotometry Method
Ting XU ; Rongli MA ; Ping FAN ; Xiaoou PAN
China Pharmacy 2001;0(09):-
AIM: To study the pharmacokinetic characteristics of domestic ofloxacin tablet. METHODS: A method of deter- mination of drug concentration in urine by UV-spectrophotometry was established. RESULTS: K = 0. 1 278/h; T1, 2 = 5. 96h, Xu0-24 = 165. 84mg; (Q) = 82. 84%. CONCLUSION: This method is simple and rapid, it is suitable for pharmacokinetics study and clinical monitoring.
4.Effect of 125I permanent implant brachytherapy on clinically localized prostate cancer
Zaisheng ZHU ; Chunting ZHANG ; Yan SHEN ; Jing FAN ; Jiang LIU ; Quanqi LIU ; Liangyou CHEN ; Rongli LUO ; Qiang FU
Cancer Research and Clinic 2016;28(10):687-691
Objective To analyze oncological outcomes of 125I permanent implant brachytherapy (125I-PIB) in clinically localized prostate cancer. Methods Between June 2008 and June 2015, 121 patients with clinically localized prostate cancer were treated with 125I-PIB, and their average age was 72.37 years old. Before treatment, the average prostate-specific antigen (PSA) level was 17.7 ng/ml, prostate volume was (51.4 ±15.0) cm3, the International Prognostic Scoring System (IPSS) score was (21.6 ±2.4) scores. The intermediate-risk and high-risk patients were treated with adjuvant endocrine or supplemental external beam radiotherapy. All patients were followed-up. Biochemical recurrence was defined as the PSA nadir plus 2.0 ng/ml. Results Average follow-up time of the 121 patients was 41.81 months. The prostate volume was (23.1 ± 10.2) cm3, and the IPSS score was (9.7±3.3) scores. Rates of 5-year overall survival, biochemical recurrence-free survival and cancer-specific survival were 86.7 %, 76.7 % and 96.5 %, respectively. 5-year biochemical recurrence-free survival rates were 88.5 %, 67.5 % and 65.2 % in the low-, intermediate-, and high-risk groups, respectively. Biochemical recurrence-free survival did not differ significantly by three risk groups (P=0.103), but the difference between high-risk and low-risk groups was statistically significant (P=0.028). According to multivariate analysis, higher prostate-specific antigen (P=0.021), higher Gleason score (P=0.023) and higher clinical T stage (P=0.037) were the significant covariates associated with biochemical recurrence-free survival. The addition of hormonal therapy or external beam radiation therapy was associated with significantly better outcomes than brachytherapy monotherapy (P=0.036, P=0.027). As for complications, there were 4 cases of surgery (trans-urethral resection of the prostate) and 4 cases of cardiovascular complications. Conclusions The 125I-PIB can bring excellent oncological outcomes and acceptable complications in patients. Adjuvant endocrine or external beam radiotherapy for the intermediate-risk and high-risk patients may improve the outcome. Factors influencing efficacy include the high PSA, Gleason score and clinical T stage.
5. Study on the improvement of Qingdaipowder Gel for external use on mice with specific dermatitis
Yurong HUANG ; Yan WANG ; Jie FAN ; Yingli WANG ; Ying JIA ; Hongqiang ZHANG ; Rongli YOU
Chinese Journal of Clinical Pharmacology and Therapeutics 2023;28(1):19-28
AIM: To study the effect of Qingdaipowder Gel (QDPG) on mice specific dermatitis (AD) model and the antibacterial effect of the ethanol extract of Qingdaipowder. METHODS: AD model of mice was established by repeated skin induction with 2,4-dinitrochlorobenzene (DNCB). Fifty-six mice were randomly divided into blank group, model group, Hydrocortisone Butyrate Cream group (Hyd, 1.5 mg/cm
6. Analysis on condom use negotiation with sex partners and condom use in female sex workers
Kun SUN ; Shenjian LI ; Jianmei ZHANG ; Rongli FAN ; Zhengchao JING ; Qingwei YANG ; Peilong LI ; Fangfang CHEN ; Lin GE ; Fan LYU ; Dongmin LI
Chinese Journal of Epidemiology 2019;40(7):795-799
Objective:
To know condom use negotiation with clients and regular sex partners and condom use in female sex workers (FSWs), and provide reference for the development of comprehensive HIV/AIDS intervention for FSWs.
Methods:
The cross sectional survey was conducted in Jianshui county and Mengzi county in Honghe Hani and Yi autonomous prefecture. A total of 476 FSWs aged 16 years and above were recruited from entertainment venues, and the information about their demographic characteristics, condom use negotiation and condom use were collected by using questionnaires. Logistic regression model was used to analyze related factors of condom use after negotiation between FSWs and clients unwilling use condom.
Results:
A total of 852 FSWs who aged (24.29±8.44) years old participated in the survey. In past month, 499 FSWs had negotiation for condom use with unwilling clients (58.6
7.Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19.
Xiaoyan LIU ; Zhe LI ; Shuai LIU ; Jing SUN ; Zhanghua CHEN ; Min JIANG ; Qingling ZHANG ; Yinghua WEI ; Xin WANG ; Yi-You HUANG ; Yinyi SHI ; Yanhui XU ; Huifang XIAN ; Fan BAI ; Changxing OU ; Bei XIONG ; Andrew M LEW ; Jun CUI ; Rongli FANG ; Hui HUANG ; Jincun ZHAO ; Xuechuan HONG ; Yuxia ZHANG ; Fuling ZHOU ; Hai-Bin LUO
Acta Pharmaceutica Sinica B 2020;10(7):1205-1215
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can cause acute respiratory distress syndrome, hypercoagulability, hypertension, and multiorgan dysfunction. Effective antivirals with safe clinical profile are urgently needed to improve the overall prognosis. In an analysis of a randomly collected cohort of 124 patients with COVID-19, we found that hypercoagulability as indicated by elevated concentrations of D-dimers was associated with disease severity. By virtual screening of a U.S. FDA approved drug library, we identified an anticoagulation agent dipyridamole (DIP) , which suppressed SARS-CoV-2 replication . In a proof-of-concept trial involving 31 patients with COVID-19, DIP supplementation was associated with significantly decreased concentrations of D-dimers ( < 0.05), increased lymphocyte and platelet recovery in the circulation, and markedly improved clinical outcomes in comparison to the control patients. In particular, all 8 of the DIP-treated severely ill patients showed remarkable improvement: 7 patients (87.5%) achieved clinical cure and were discharged from the hospitals while the remaining 1 patient (12.5%) was in clinical remission.